Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Bioventus (BVS) Shares Outstanding (2021 - 2026)

Bioventus filings provide 5 years of Shares Outstanding readings, the most recent being $67.1 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 2.04% to $67.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $67.1 million, a 2.04% increase, with the full-year FY2025 number at $67.1 million, up 2.04% from a year prior.
  • Shares Outstanding hit $15.8 million in Q4 2025 for Bioventus, down from $67.0 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $67.0 million in Q3 2025 to a low of $15.8 million in Q4 2021.
  • Median Shares Outstanding over the past 5 years was $61.9 million (2022), compared with a mean of $47.2 million.
  • Biggest five-year swings in Shares Outstanding: plummeted 74.74% in 2024 and later soared 319.54% in 2025.
  • Bioventus' Shares Outstanding stood at $59.5 million in 2021, then grew by 4.22% to $62.1 million in 2022, then rose by 1.94% to $63.3 million in 2023, then rose by 3.94% to $65.8 million in 2024, then increased by 2.04% to $67.1 million in 2025.
  • The last three reported values for Shares Outstanding were $67.1 million (Q4 2025), $67.0 million (Q3 2025), and $66.9 million (Q2 2025) per Business Quant data.